checkAd
    Startseite > Aktien > Edgewise Therapeutics > Nachrichten
    Edgewise Therapeutics Aktie
    17,050
     
    USD
    +5,44 %
    +0,880 USD
    Letzter Kurs 02:00:00 Nasdaq
    17,030
     
    USD
    1.200 STK
    Geldkurs 29.04.24
    17,050
     
    USD
    1.600 STK
    Briefkurs 29.04.24
    ISIN: US28036F1057 · WKN: A2QRZ8 · SYM: EWTX · USA

    Neueste Nachrichten

    Edgewise Receives European Medicines Agency (EMA) Orphan Drug Designations for Sevasemten (EDG-5506) for the Treatment of Becker and Duchenne Muscular Dystrophies
    23.04.24 · Business Wire (engl.) · Edgewise Therapeutics
    Edgewise Therapeutics Announces Positive Two-Year Topline Results from the ARCH Open Label Trial of Sevasemten (EDG-5506) in Adults with Becker Muscular Dystrophy (Becker)
    15.04.24 · Business Wire (engl.) · Edgewise Therapeutics
    Edgewise Therapeutics Announces Upcoming Podium Presentation at the American College of Cardiology's 2024 Annual Scientific Session
    28.03.24 · Business Wire (engl.) · Edgewise Therapeutics
    Edgewise Therapeutics to Present at the Cantor Virtual Muscular Dystrophy Symposium on April 2, 2024
    27.03.24 · Business Wire (engl.) · Edgewise Therapeutics
    Edgewise Therapeutics to Present at the Leerink Partners Global Biopharma Conference on March 11, 2024
    05.03.24 · Business Wire (engl.) · Edgewise Therapeutics
    Edgewise Therapeutics to Present on EDG-5506 for the Treatment of Becker Muscular Dystrophy at the 2024 MDA Clinical and Scientific Conference
    28.02.24 · Business Wire (engl.) · Edgewise Therapeutics
    Edgewise Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
    22.02.24 · Business Wire (engl.) · Edgewise Therapeutics
    Edgewise Receives U.S. FDA Fast Track Designation for EDG-5506 for the Treatment of Duchenne Muscular Dystrophy (Duchenne)
    13.02.24 · Business Wire (engl.) · Edgewise Therapeutics
    Edgewise Therapeutics Announces Pricing of $240 Million Underwritten Offering of Common Stock
    19.01.24 · Business Wire (engl.) · Edgewise Therapeutics
    Edgewise Therapeutics Highlights 2023 Accomplishments and Anticipated Milestones for 2024 at the 42nd Annual J.P. Morgan Healthcare Conference
    09.01.24 · Business Wire (engl.) · Edgewise Therapeutics
    Edgewise Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 9, 2024
    19.12.23 · Business Wire (engl.) · Edgewise Therapeutics
    Edgewise Therapeutics Launches First of Its Kind Educational Website Dedicated to the Becker Muscular Dystrophy Community
    18.12.23 · Business Wire (engl.) · Edgewise Therapeutics